Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy. Issue 1 (24th December 2020)

• Record Type: Journal Article
• Authors: Yonishi, Hiroaki; Namba-Hamano, Tomoko; Hamano, Takayuki; Hotta, Masaki; Nakamura, Jun; Sakai, Shinsuke; Minami, Satoshi; Yamamoto, Takeshi; Takahashi, Atsushi; Kobayashi, Wataru; Maeda, Ikuhiro; Hidaka, Yoh; Takabatake, Yoshitsugu; Sakai, Norio; Isaka, Yoshitaka
• Is Part Of: Nephrology dialysis transplantation. Volume 37:Issue 1(2022)
• Page Start: 53
• Page End: 62
• Publication Date: 2020-12-24
• Subjects: biomarkers -- Fabry disease -- globotriaosylceramide (Gb3) -- podocyte injury -- urinary mulberry body; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfaa298
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: Background: The inability of enzyme replacement therapy (ERT) to prevent progression of Fabry nephropathy (FN) in the presence of >1 g/day proteinuria underscores the necessity of identifying effective biomarkers for early diagnosis of FN preceding proteinuria. Here we attempted to identify biomarkers for early detection of FN. Methods: Fifty-one Fabry disease (FD) patients were enrolled. Urinary mulberry bodies (uMBs) were immunostained for globotriaosylceramide (Gb3) and renal cell markers to determine their origin. The association between semiquantitative uMB excretion and the histological severity of podocyte vacuolation was investigated in seven patients using the vacuolated podocyte:glomerular average area ratio. The association between the semiquantitative estimate of uMB excretion and duration of ERT was analyzed. A longitudinal study was conducted to assess the effect of ERT on uMB excretion. Results: Thirty-two patients (63%) had uMBs, while only 31% showed proteinuria. The uMBs were positive for Gb3, lysosomal-associated membrane protein 1 and podocalyxin, suggesting they were derived from lysosomes with Gb3 accumulation in podocytes. We observed more severe podocyte vacuolation with increased uMB excretion (P = 0.03 for trend); however, the same was not observed with increased proteinuria. The percentage of patients with substantial uMB excretion increased with shorter ERT duration (P = 0.018). Eighteen-month-long ERT reduced uMB excretion (P = 0.03) without affecting proteinuria. Conclusions: uMB excretion, implying ongoing podocyte injury, preceded proteinuria in most patients. Semiquantitative uMB estimates can serve as novel biomarkers for early FN diagnosis and for monitoring the efficacy of FD-specific therapies.